Treatment Study of Denintuzumab Mafodotin (SGN-CD19A) Plus RICE Versus RICE Alone for Diffuse Large B-Cell Lymphoma
Status:
Terminated
Trial end date:
2018-04-20
Target enrollment:
Participant gender:
Summary
The purpose of this randomized, open-label study is to evaluate the safety and efficacy of
denintuzumab mafodotin plus RICE (rituximab, ifosfamide, carboplatin, and etoposide) when
compared to RICE alone in the treatment of patients with relapsed or refractory diffuse large
B-cell lymphoma (DLBCL) or Grade 3b follicular lymphoma. Eligible patients must also be
candidates for autologous stem cell transplant. Patients will be randomly assigned in a 1:1
ratio to receive 3 cycles of study treatment with either denintuzumab mafodotin + RICE or
RICE alone. The study will assess whether there is a difference between the 2 groups in the
side effects that are reported and the number of patients who achieve complete remission at
the end of their study treatment.